Alterations of glucose metabolism during treatment with clozapine or amisulpride: Results from a prospective 16-week study

Journal of Psychopharmacology

Volumn 21, Issue 4, 2007, Pages 400-404

  Rettenbacher, Maria A ^a,c   Hummer, Martina ^a   Hofer, Alex ^a   Baumgartner, Susanne ^a   Ebenbichler, Christoph ^b   Edlinger, Monika ^a   Kemmler, Georg ^a   Lechleitner, Monika ^b   Wolfgang Fleischhacker, W ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Antipsychotics; Glucose metabolism; Insulin; Weight

Indexed keywords

AMISULPRIDE; CLOZAPINE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC DISORDER; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CLOZAPINE; FEMALE; GLUCOSE; GLUCOSE METABOLISM DISORDERS; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SULPIRIDE;

EID: 34447546638     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106069467     Document Type: Article

References (37)

1. Braceland F.J., Meduna L.J., Vaichulis J.A. (1945) Delayed action of insulin in schizophrenia, Am J Psychiat 102: 108 - 110
2. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., Lehman A. (2000) Prevalence and correlates of diabetes in national schizophrenia samples, Schizophr Bull 26: 903 - 912
3. Ebenbichler C., Kirchmair R., Egger C., Patsch J.R. (1995) Postprandial lipemia and atherosclerosis, Curr Opin Lipidol 6: 286 - 290
4. Ebenbichler C.R., Laimer M., Eder U., Mangweth B., Weiss E., Hofer A., Hummer M., Kemmler G., Lechleitner M., Patsch J.R., Fleischhacker W.W. (2003) Olanzapine induces insulin resistance: results from a prospective study, J Clin Psychiat 64: 1436 - 1439
5. Fric M., Laux G. (2003) Prolactin levels and symptoms of hyperprolactinemia in patients treated with amisulpride, risperidone, olanzapine and quetiapine, Psychiatr Prax 30 (Suppl 2): 97 - 101
6. Haffner S.M., Kennedy E., Gonzalez C., Stern M.P., Miettinen H. (1996) A prospective analysis of the HOMA model: the Mexico City Diabetes Study, Diab Care 19: 1138 - 1141
7. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, N Engl J Med 339: 229 - 234
8. Henderson D.C. (2001) Clozapine: diabetes mellitus, weight gain and lipid abnormalities, J Clin Psychiat 62: 39 - 44
9. Hermans M.P., Levy J.C., Morris R.J., Turner R.C. (1999) Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes, Diabetologia 42: 678 - 687
10. Jin H., Meyer J.M., Jeste D.V. (2002) Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases, Ann Clin Psychiat 14: 59 - 64
11. Kristensen S.H., Porksen N.K. (2003) Clozapine and diabetic ketoacidosis, Ugeskr Laeger 165: 475 - 476
12. Kurzthaler I., Fleischhacker W.W. (2001) The clinical implications of weight gain in schizophrenia, J Clin Psychiat 62 (Suppl. 7): 32 - 37
13. Lafayette J.M., Pirl W.F., Henderson D.C. (2003) Lowdose clozapine and diabetic ketoacidosis, Psychosomatics 44: 249 - 252
14. Lean M.E., Powrie J.K., Anderson A.S., Garthwaite P.H. (1990) Obesity, weight loss and prognosis in type 2 diabetes, Diabet Med 7: 228 - 233
15. Liebzeit K.A., Markowitz J.S., Caley C.F. (2001) New onset diabetes and atypical antipsychotics, Eur Neuropsychopharmacol 11: 25 - 32
16. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. (1985) Homeostasis Model Assessment: insulin resistance and beta-call function from fasting plasma glucose and insulin concentrations in man, Diabetologia 28: 412 - 419
17. Melkersson K.I., Hulting A.L. (2001) Insulin and leptin levels in patients with schizophrenia or related psychosis: a comparison between different antipsychotic agents, Psychopharmacology 154: 205 - 212
18. Melkersson K.I., Hulting A.L., Brismar K.E. (2000) Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses, J Clin Psychiat 61: 742 - 749
19. Meyer J.M. (2002) A retrospective comparison of weight, lipid and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year, J Clin Psychiat 63: 425 - 433
20. Mir S., Taylor D. (2001) Antipsychotics and hyperglycemia, Int Clin Psychopharmacology 16: 63 - 73
21. Mukherjee S., Decina P., Bocola V., Saraceni F., Scapicchio P.L. (1996) Diabetes mellitus in schizophrenia patients, Compr Psychiatry 37: 68 - 73
22. Newcomer J.W. (2004) Abnormalities of glucose metabolism associated with atypical antipsychotic drugs, J Clin Psychiat 65 (Suppl. 18): 36 - 46
23. Newcomer J.W. (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review, CNS Drugs 19 (Suppl 1): 1 - 93
24. Patsch J.R. (1994) Triglyceride-rich lipoproteins and atherosclerosis, Atherosclerosis 110: S23 - S26
25. Patsch J.R., Miesenbock G., Hopferwieser T., Muhlberger V., Knapp E., Dunn J.K., Gotto A.M. Jr, Patsch W. (2002) Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state, Arteroscl Thromb 12: 1336 - 1345
26. Reaven G., Abbasi F., McLaughlin T. (2004) Obesity, insulin resistance, and cardiovascular disease, Recent Prog Horm Res 59: 207 - 223
27. Ruige J.B., Assendelft W.J., Dekker J.M., Kostense P.J., Heine R.J., Bouter L.M. (1998) Insulin and risk of cardiovascular disease: a meta-analysis, Circulation 97: 996 - 1001
28. Sechter D., Peuskens J., Fleurot O., Rein W., Lecrubier Y. (2002) Amisulpride vs. risperidone in chronic schizophrenia: results 6-month double-blind study, Neuropsychopharmacology 27: 1071 - 1081
29. Shulman G.I. (2000) Cellular mechanisms of insulin resistance, J Clin Investigation 106: 171 - 176
30. Tabata H., Kikuoka M., Kikuoka H., Bessho H., Hirayama J., Hanabusa T., Kubo K., Momotani Y., Sanke T., Nanjo K. (1987) Characteristics of Diabetes mellitus in schizophrenia patients, J Med Assoc Thailand 70 (Suppl. 2): 90 - 93
31. Uvnas-Moberg K., Ahlenius S., Alster P., Hillegaart V. (1996) Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat, Neuroendocrinology 63: 269 - 274
32. Wehring H.J., Kelly D.L., Love R.C., Conley R.R. (2003) Diabetic ketoacidosis after long-term clozapine treatment, Am J Psychiat 160: 2241 - 2242
33. Wilson D.R., D'Souza L., Sarkar N., Newton M., Hammond C. (2003) New-onset diabetes and ketoacidosis with atypical antipsychotics, Schizophr Res 59: 1 - 6
34. Wirshing D.A., Boyd J.A., Meng L.R., Ballon J.S., Marder S.R., Wirshing WC (2000) The effects of novel antipsychotics on glucose and lipid levels, J Clin Psychiat 63: 856 - 865
35. Wirshing D.A., Spellberg B.J., Erhart S.M., Marder S.R., Wirshing W.C. (1998) Novel Antipsychotics and New Onset Diabetes, Biol Psychiat 44: 778 - 783
36. Wozniak K.M. (1991) Hyperglycemia properties of serotonin receptor antagonists, Life Sci 49: 101 - 109
37. Yavuz D., Deyneli O., Akpinar I., Yildiz E., Gozu H., Sezgin O., Haklar G., Akalin S. (2003) Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women, Eur J Endocrinol 149: 187 - 193